1 p inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate.

2 e, 400 mg three times a day for 2 weeks; and bismuth subsalicylate, 262 mg four times a day for 2 wee

3  were analyzed before and after ingestion of bismuth subsalicylate (524 mg four times a day) for 3-7

4                 In this study the ability of bismuth subsalicylate, a compound that binds H2S, to red

5 nt relationship between the concentration of bismuth subsalicylate and H2S release.

6                                              Bismuth subsalicylate, and 5-amniosalicylates are therap

7 nd rat feces were incubated with and without bismuth subsalicylate, and gas production was measured.

8 t the addition of a proton pump inhibitor or bismuth subsalicylate does not increase cure rate.

9  with simultaneous iodinated intravenous and bismuth subsalicylate enteric contrast material at DE CT

10                We theorized that integrating bismuth subsalicylate into a quadruple therapy regimen c

11                                   Regimen 3, bismuth subsalicylate + metronidazole + tetracycline + a

12  a rabbit in which iodinated intravenous and bismuth subsalicylate oral contrast media were administe

13 th disalicylate, a model for the metallodrug bismuth subsalicylate (Pepto-Bismol).

14                   Treatment of subjects with bismuth subsalicylate produced a >95% reduction in fecal

15 ation with omeprazole (regimen 3; n = 4), or bismuth subsalicylate (regimen 4; n = 6).

16                               The ability of bismuth subsalicylate to dramatically reduce H2S could p

17 consisted of vonoprazan (20 mg) twice daily, bismuth subsalicylate twice daily, metronidazole (400 mg